P38 Inhibitor (4) ( DrugBank: - )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
46	Malignant rheumatoid arthritis	2

46. Malignant rheumatoid arthritis

---

Clinical trials : 4,356 /  Drugs : 2,567 - (DrugBank : 415) / Drug target genes : 192 - Drug target pathways : 228

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00303563 (ClinicalTrials.gov)	April 2006	16/3/2006	A Study of P38 Inhibitor (4) Monotherapy in Patients With Active Rheumatoid Arthritis	A Randomized, Double-blind Study to Compare the Effect of RO4402257 Monotherapy and Methotrexate Monotherapy on Disease Response in Patients With Active Rheumatoid Arthritis.	Rheumatoid Arthritis	Drug: P38 Inhibitor (4);Drug: Placebo	Hoffmann-La Roche	NULL	Completed	18 Years	N/A	Both	204	Phase 2	United States;Canada;Croatia;Czech Republic;France;Italy;Mexico;Romania;Serbia;South Africa;Spain;Taiwan;Former Serbia and Montenegro
2	NCT00316771 (ClinicalTrials.gov)	November 2005	20/4/2006	A Study of P38 Inhibitor (4) in Patients With Active Rheumatoid Arthritis (RA) on Stable Methotrexate Therapy	A Randomized, Double-blind, Placebo-controlled, Study to Determine the Efficacy and Safety of 5 Dose Regimens of RO4402257 in Patients With Active Rheumatoid Arthritis (RA) on Stable Methotrexate (MTX) Therapy.	Rheumatoid Arthritis	Drug: P38 Inhibitor (4) 150mg;Drug: P38 Inhibitor (4) 25mg;Drug: P38 Inhibitor (4) 300mg;Drug: P38 Inhibitor (4) 50mg;Drug: P38 Inhibitor (4) 75mg;Drug: Placebo	Hoffmann-La Roche	NULL	Completed	18 Years	N/A	Both	374	Phase 2	South Africa;Spain;United Kingdom;United States;Australia;Brazil;Canada;Estonia;Germany;Greece;Ireland;Mexico;New Zealand;Poland